New drug may offer safer relief for painful mouth condition
NCT ID NCT06260904
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This study tested two drugs, apremilast and methotrexate, added to standard steroid treatment for oral lichen planus, a chronic inflammatory mouth condition causing pain and sores. 64 adults with moderate to severe disease who didn't respond to topical steroids took either apremilast or methotrexate alongside prednisolone for 12 weeks. The goal was to see which combination better reduces pain and disease severity while limiting steroid side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL LICHEN PLANUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AIIMS Bhubaneswar
Bhubaneswar, Odisha, 751019, India
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apremilast and methotrexate
What this could lead to
If apremilast works as well as methotrexate but with fewer side effects, it could become a safer add-on treatment for oral lichen planus.
What could go wrong
This is a small, completed Phase 4 trial with only 64 participants. Results may not apply to everyone, and both drugs can cause side effects like nausea or liver issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.